TXA for postpartum hemorrhage prevention after cesarean
Loïc Sentilhes, MD, PHD, presented data on tranexamic acid (TXA) for the prevention of postpartum hemorrhage after cesarean delivery: the TRAAP2 trial, on Wednesday at SMFM's 2021 Virtual Annual Meeting.
This article is on based on information presented at the Society for Maternal-Fetal Medicine’s 2021 Virtual Annual Meeting, which is being held Jan. 25 to Jan. 30.
For more information and registration details, visit SMFM.org.
“As you all know, postpartum hemorrhage is a major cause of maternal death and severe maternal morbidity,” said Loïc Sentilhes, MD, of the Bordeaux University Hospital, France, presenting on behalf of the French Groupe de Recherche en Obstétrique et Gynécologie (GROG). “Today the prophylactic administration of a uterotonic is the only procedure that has been proven to reduce PPH after delivery and therefore is recommended by authorities for all women worldwide.”
TXA, which is an antifibrinolytic agent, reduces bleeding in elective surgery; and mortality in patients with extracranial and mild to moderate intracranial trauma, without increasing vascular occlusive events, he said. TXA has been demonstrated to reduce bleeding-related mortality in patients with PPH, especially when it is administered shortly after delivery, which suggests that it may prevent, rather than treat, coagulopathy after delivery.
In terms of vaginal delivery, Sentilhes said that they found no significant reduction in blood loss of at least 500 ml in women who received 1g of prophylactic TXA at delivery.
Reducing costs and increasing accessibility key to enhancing STI testing among youth
August 6th 2024A study presented at the Infectious Disease Society for Obstetrics and Gynecology 2024 Annual Meeting highlights the importance of affordability and convenience in boosting STI test uptake among adolescents and young adults.
Read More
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More
